In response to mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study Journal of Perinatology (2013) 33, 165-166; doi:10.1038 /jp.2012 A large subset of the data presented in the article Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study were published by the same authors in two abstracts in 2007.
1, 2 The first abstract reported that the Curosurf population has a lower mortality rate than Infasurf or Survanta. The second abstract reported that the same Curosurf population had a shorter length of stay than either the Survanta or Infasurf population. From the initial placebo-controlled trials of lung surfactant replacement therapy, the mortality improvement due to surfactant therapy resulted in an increase, not a decrease, in the length of stay. Preventing death from Respiratory Distress Syndrome will of course produce a much longer length of stay than dying from Respiratory Distress Syndrome. One report showed the length of stay tripled, from 20-61 days for surfactant-treated infants compared with placebo.
3 How, in this population, was it possible for Curosurf patients to have both a lower mortality and a shorter length of stay? The self-evident answer is that Curosurf was administered to more patients who had low mortality risk. Similar patients cared for by physicians who use Infasurf and Survanta are not included in the database, because they did not receive any surfactant therapy at all.
The article as published, omitted the length of stay data and reported only the mortality data. It does have multiple regression analyses 'correcting' for possible differences in risk among patients enrolled. Those techniques cannot correct for systematic differences in patient selection. The paper omits this data, which shows that the populations were different.
Omission of the length of stay data created an illusory 'mortality advantage' for the surfactant of the study's sponsor. I wrote Editor Lawson in September 2011, identified the omitted data and requested that this paper be retracted as 'unreliable' (which is the standard for retractions that is used by the Committee on Publication Ethics, which lists the Journal of Perinatology is a member 4 ). Dr Lawson chose not to retract the paper. The 'unreliable' standard is the proper one for peer-reviewed journals. This paper as e-publishedFwithout the length of stay dataFis at least 'unreliable' and should be retracted. Dr Egan discusses the increased length of stay (LOS) resulting from improvement in mortality due to surfactant therapy in studies comparing surfactant vs placebo. Based on evidence, the introduction of surfactant therapy has led to significantly decreased mortality and morbidity without increasing resource utilization. The statements of Dr Egan regarding inverse correlation between mortality and LOS are based on a very old study (ref 3 in his letter) comparing surfactant with placebo in a different 'era' of neonatology, where respiratory distress syndrome (RDS) was the major cause of death and had a major influence on LOS. Most important is the fact that surfactant therapy compared with placebo has shown decrease in cost both in infants who survived as well as in infants who died. Subsequent studies on resource utilization are clearly different and these have reported LOS in patients who received one of the three animal-derived surfactants. 1,2 Baroutis et al.
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3 reported decreased mortality and significantly shorter LOS with poractant alfa (PA), when compared to alveofact or beractant (BE) in a randomized, controlled trial. Fujii et al.
4 reported a nonsignificant decrease in mortality (8 vs 19%) and shorter LOS in a PA-treated group compared with that in the BE-treated group (87 vs 97 days, P ¼ 0.179). In two randomized, controlled trials comparing PA and BE, incidence of patent ductus arteriosus (PDA), as well as the need for medical or surgical ligation of PDA, were significantly less in patients treated with PA, 4,5 which might therefore contribute to shorter LOS. In a study comparing high vs low dose surfactant therapy, LOS was shorter in the high dose group when compared with low dose group (82 vs 99 days).
6
A recently published systematic review and meta-analysis, 7 demonstrated a good correlation between higher surfactant efficacy (mortality reduction) and reduced LOS with poractant alfa (PA). Indeed, in the meta-analysis, PA was associated with both a significant reduced risk of death vs BE (P ¼ 0.02) and a significantly shorter LOS (weighted mean difference: À26.3 [95% CI: À36.5 to À16.07]; P<0.00001). In the most recent randomized trial comparing PA with BE, LOS was not increased in PA group despite a 50% reduction in mortality rate in the PA-treated group (9.8 vs 20%).
8
In light of the evidence cited above, it is incorrect to assume that decreased mortality will automatically lead to longer LOS, especially, when comparing treatment with different surfactants, different timing of administration such as early vs delayed treatment, and different doses such as high vs low dose. It is very likely that higher doses of PA contributed to the positive results seen with PA in all the randomized, controlled trials as well as from meta-analysis published to date. Reasons for shorter LOS accompanying decreased mortality are likely multifactorial. For example, in six of the randomized trials published to date comparing PA with BE, PA treatment was associated with faster weaning of oxygen and pressures, less need for redosing, earlier extubations, less PDA and air-leaks, and improved survival free of bronchopulmonary dysplasia. All of these secondary outcomes might have contributed to the shorter LOS observed in PA treated-infants.
Furthermore, we did not omit LOS results to create an illusory 'mortality advantage' as stated by Dr Egan in his letter. Other retrospective studies comparing mortality differences between animal-derived surfactants do not include LOS amongst covariates in the mortality analysis and therefore our manuscript is entirely consistent with previous and also subsequent study designs in the field of retrospective mortality analyses.
9,10 In fact, Trembath et al., 10 in a recent report involving 59 342 infants treated with surfactants concluded that, 'Poractant alfa and calfactant were associated with lower incidence of morbidity and mortality as compared to beractant in premature infants. Given that further randomized controlled trials comparing surfactants is unlikely, our findings suggest that the differences in efficacy might be important for clinical practice'. Treatment with PA was associated with fewer air leaks in the first week vs BE and CA, OR ¼ 0.80 (95% CI; 0.69, 0.94) and 0.69 (0.59, 0.82), respectively, and treatment with PA or CA vs BE was associated with lower incidence of BPD, OR ¼ 0.92 (0.88, 0.95) and 0.89 (0.85, 0.93) and mortality, OR ¼ 0.71 (0.65, 0.77) and 0.92 (0.85, 0.99), respectively, which persisted after adjustment.
10 These study findings are entirely consistent with our study findings and other randomized studies involving PA and BE. Furthermore, we have clearly stated in our previous response letter
